

Denmark

Recent and planned developments in pharmaceutical policies 2018

Special topic: national incentives and derogatory procedures for orphan medicines

CHANGES IN PRICING

Out- patient

No changes in the way we set prices in 2018.

Future plans

Working on development of ERP in Denmark. The policy will apply for the companies who aren't a part of The Danish Association of the Pharmaceutical Industry (LIF) and therefore a part of the voluntary price cap agreements between LIF, Danish Regions and the Ministry of Health. Expected to take effect during 2020.

CHANGES IN REIMBURSEMENT

Out-patient

Some medicine to the treatment of migraine, Parkinson's disease, asthma, COPD and overactive bladder syndrome has changed reimbursement status, due to cost and guidelines.

Future plans

From 2019 a pilot scheme for conditional reimbursement under terms of risk sharing for two pharmaceuticals.

OTHERS CHANGES

- The authorities are working with a new agreement with the industry about changes in list prices like the last agreement from 2017-2019. The new period will start spring 2019
- Working with at new set-up with reference prices – we can tell about it next meeting | April 2019.

SPECIAL TOPIC: National Incentives and Derogatory Procedures for Orphan Medicines

The Danish Medicines Council assesses new hospital medicines (incl. orphan drugs) and several medicines within the same therapeutic area

The Danish Medicines Council was established on January 1, 2017 by the board of Danish Regions. The Council is based on experiences from the Danish Council for the Use of Expensive Hospital Medicines (RADS) and "Koordineringsrådet for ibrugtagning af sygehusmedicin" (KRIS).

The Danish Medicines Council is to:

- Ensure fast and homogeneous use of new and existing medicines across hospitals and regions
- Impose stricter requirements for documentation to support that patients will benefit from new and existing medicines
- Enhance the basis for Amgros' price negotiations and calls for tenders. Amgros is the joint procurement service for the Danish regions and is mostly concerned with procurement of medicines for hospital use.

If the Danish medicines council say NO to standard usages, The doctors in the hospital can applied for a single patients usages.